JP2015509707A5 - - Google Patents

Download PDF

Info

Publication number: JP2015509707A5
Authority: JP; Japan
Prior art keywords: seq; variant; polypeptide; length; amino acids
Prior art date: 2013-01-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2014553750A

Other languages

English (en)

Japanese (ja)

Other versions

JP6306514B2 (ja

JP2015509707A (ja

Filing date

2013-01-28

Publication date

2016-03-17

2012-01-27 Priority claimed from EP12382031.8A external-priority patent/EP2620446A1/en

2013-01-28 Application filed filed Critical

2015-04-02 Publication of JP2015509707A publication Critical patent/JP2015509707A/ja

2016-03-17 Publication of JP2015509707A5 publication Critical patent/JP2015509707A5/ja

2018-04-04 Application granted granted Critical

2018-04-04 Publication of JP6306514B2 publication Critical patent/JP6306514B2/ja

Status Active legal-status Critical Current

2033-01-28 Anticipated expiration legal-status Critical

Links

108090000765 processed proteins & peptides Proteins 0.000 claims description 85
150000001413 amino acids Chemical class 0.000 claims description 72
230000002163 immunogen Effects 0.000 claims description 29
102000004196 processed proteins & peptides Human genes 0.000 claims 71
229920001184 polypeptide Polymers 0.000 claims 70
108091033319 polynucleotide Proteins 0.000 claims 32
102000040430 polynucleotide Human genes 0.000 claims 32
239000002157 polynucleotide Substances 0.000 claims 32
102000039446 nucleic acids Human genes 0.000 claims 19
108020004707 nucleic acids Proteins 0.000 claims 19
150000007523 nucleic acids Chemical class 0.000 claims 19
241000700605 Viruses Species 0.000 claims 16
239000013604 expression vector Substances 0.000 claims 15
229960005486 vaccine Drugs 0.000 claims 13
210000004027 cell Anatomy 0.000 claims 12
125000003275 alpha amino acid group Chemical group 0.000 claims 8
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
210000001744 T-lymphocyte Anatomy 0.000 claims 4
206010059866 Drug resistance Diseases 0.000 claims 2
208000031886 HIV Infections Diseases 0.000 claims 2
208000037357 HIV infectious disease Diseases 0.000 claims 2
230000000798 anti-retroviral effect Effects 0.000 claims 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
230000035772 mutation Effects 0.000 claims 2
108020005345 3' Untranslated Regions Proteins 0.000 claims 1
125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
108020004705 Codon Proteins 0.000 claims 1
102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 1
108010076504 Protein Sorting Signals Proteins 0.000 claims 1
239000002671 adjuvant Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
210000005260 human cell Anatomy 0.000 claims 1
239000003550 marker Substances 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
239000003446 ligand Substances 0.000 description 2
108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
241001195348 Nusa Species 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
239000011324 bead Substances 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1

JP2014553750A 2012-01-27 2013-01-28 Ｈｉｖワクチン接種のための免疫原 Active JP6306514B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP12382031.8		2012-01-27
EP12382031.8A EP2620446A1 (en)	2012-01-27	2012-01-27	Immunogens for HIV vaccination
PCT/EP2013/051596 WO2013110818A2 (en)	2012-01-27	2013-01-28	Immunogens for hiv vaccination

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018041572A Division JP6749357B2 (ja)	2012-01-27	2018-03-08	Ｈｉｖワクチン接種のための免疫原

Publications (3)

Publication Number	Publication Date
JP2015509707A JP2015509707A (ja)	2015-04-02
JP2015509707A5 true JP2015509707A5 (2)	2016-03-17
JP6306514B2 JP6306514B2 (ja)	2018-04-04

Family

ID=47603800

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2014553750A Active JP6306514B2 (ja)	2012-01-27	2013-01-28	Ｈｉｖワクチン接種のための免疫原
JP2018041572A Active JP6749357B2 (ja)	2012-01-27	2018-03-08	Ｈｉｖワクチン接種のための免疫原

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2018041572A Active JP6749357B2 (ja)	2012-01-27	2018-03-08	Ｈｉｖワクチン接種のための免疫原

Country Status (16)

Country	Link
US (4)	US9988425B2 (2)
EP (3)	EP2620446A1 (2)
JP (2)	JP6306514B2 (2)
KR (2)	KR102140778B1 (2)
CN (2)	CN104080800B (2)
AU (2)	AU2013213564B2 (2)
BR (1)	BR112014018396B1 (2)
CA (1)	CA2862172C (2)
ES (1)	ES2932407T3 (2)
IL (2)	IL233771B (2)
IN (1)	IN2014DN06164A (2)
MX (2)	MX358711B (2)
NZ (3)	NZ734689A (2)
RU (2)	RU2721274C2 (2)
WO (1)	WO2013110818A2 (2)
ZA (1)	ZA201405204B (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9090673B2 (en)	2003-12-12	2015-07-28	City Of Hope	Synthetic conjugate of CpG DNA and T-help/CTL peptide
ES2467108T3 (es)	2008-12-09	2014-06-11	Gilead Sciences, Inc.	Moduladores de receptores tipo toll
EP2620446A1 (en)	2012-01-27	2013-07-31	Laboratorios Del Dr. Esteve, S.A.	Immunogens for HIV vaccination
CN107635579A (zh) *	2014-03-21	2018-01-26	纽泰克温图斯公司	非天然发生的猪生殖和呼吸综合征病毒(prrsv)和使用方法
PT3166607T (pt)	2014-07-11	2022-12-07	Gilead Sciences Inc	Moduladores de receptores de tipo toll para o tratamento do vih
CA2960436C (en)	2014-09-16	2021-01-05	Gilead Sciences, Inc.	Solid forms of a toll-like receptor modulator
MA40783A (fr)	2014-10-03	2017-08-08	Los Alamos Nat Security Llc	Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2020237027A1 (en) *	2019-05-22	2020-11-26	Gilead Sciences, Inc.	Combination of a tlr7 modulating compound and an hiv vaccine
EP3972642A1 (en) *	2019-05-22	2022-03-30	Aelix Therapeutics S.L.	Dosage regimens for vaccines
CN114761041A (zh)	2019-07-16	2022-07-15	吉利德科学公司	Hiv疫苗及其制备和使用方法
CA3161633A1 (en) *	2019-11-14	2021-05-20	Aelix Therapeutics, S.L.	Dosage regimens for vaccines
EP4149530A1 (en)	2020-05-12	2023-03-22	Janssen Vaccines & Prevention B.V.	Administration of homologous adenoviral vectors
US20220118081A1 (en)	2020-10-20	2022-04-21	Janssen Vaccines & Prevention B.V.	HIV vaccine regimens
EP4277652A1 (en)	2021-01-14	2023-11-22	Gilead Sciences, Inc.	Hiv vaccines and methods of using
WO2024084441A1 (en)	2022-10-19	2024-04-25	Aelix Therapeutics, S.L.	Combination hiv vaccine
EP4417974A1 (en)	2023-02-17	2024-08-21	Fundació Privada Institut de Recerca de la SIDA-Caixa	Cd33 as a biomarker of hiv control
WO2025017540A1 (en)	2023-07-20	2025-01-23	Aelix Therapeutics, S.L.	Method of treatment of hiv infection with vaccine
CN118389553A (zh) *	2024-03-01	2024-07-26	中国科学技术大学	免疫增效rna分子及其组合物、疫苗与试剂盒

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE787901A (fr)	1971-09-11	1972-12-18	Freistaat Bayern Represente Pa	Vaccin antivariolique
US6001977A (en)	1984-08-22	1999-12-14	The United States Of America As Represented By The Department Of Health And Human Services	Cloning and expression of HTLV-III DNA
US5554372A (en)	1986-09-22	1996-09-10	Emory University	Methods and vaccines comprising surface-active copolymers
US6294322B1 (en)	1988-01-26	2001-09-25	The United States Of America As Represented By The Department Of Health And Human Services	Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5081226A (en)	1986-12-30	1992-01-14	The United States Of America As Represented By The Department Of Health And Human Services	Synthetic peptides sharing sequence homology with the HIV envelope protein
US5976541A (en)	1988-01-26	1999-11-02	The United States Of America As Represented By The Department Of Health And Human Services	Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US5128319A (en)	1987-08-28	1992-07-07	Board Of Regents, The University Of Texas System	Prophylaxis and therapy of acquired immunodeficiency syndrome
US6210873B1 (en)	1987-08-28	2001-04-03	Board Of Regents, The University Of Texas System	Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
GB8918200D0 (en)	1989-08-09	1989-09-20	Medical Res Council	The peptide fragments of hiv
US6174666B1 (en)	1992-03-27	2001-01-16	The United States Of America As Represented By The Department Of Health And Human Services	Method of eliminating inhibitory/instability regions from mRNA
US7319000B1 (en)	1992-09-16	2008-01-15	Board Of Regents, The University Of Texas System	Compositions and methods for eliciting immune or anti-infective responses
CA2164818C (en)	1993-06-09	2003-09-23	Charles D.Y. Sia	Tandem synthetic hiv-1 peptides
ES2323909T3 (es)	1994-12-24	2009-07-27	Cambridge University Technical Services Limited	Mejoras introducidas en la funcion endometrial.
UA68327C2 (en)	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en)	1996-02-09	2000-08-01	Ludwig Institute For Cancer Research	Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
JP2001505763A (ja)	1996-08-09	2001-05-08	バイラル・テクノロジーズ・インコーポレーテツド	Ｈｉｖｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法
US6093400A (en)	1996-08-09	2000-07-25	Cel Sci Corporation	Modified HGP-30 peptides, conjugates, compositions and methods of use
US6031647A (en)	1996-10-23	2000-02-29	Nortel Networks Corporation	Stable power control for optical transmission systems
US5972339A (en)	1997-11-13	1999-10-26	The General Hospital Corporation	Method of eliciting anti-HIV-1 helper T cell responses
US20040106136A1 (en)	1999-01-25	2004-06-03	Musc Foundation For Research Development	Method for testing drug susceptibility of HIV
CN1297932A (zh) *	1999-11-30	2001-06-06	上海博容基因开发有限公司	一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
AU784679B2 (en) *	1999-12-23	2006-05-25	International Aids Vaccine Initiative	Improvements in or relating to immune responses to HIV
FR2803307A1 (fr)	1999-12-30	2001-07-06	Centre Nat Rech Scient	Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
US20040105871A1 (en)	2000-03-02	2004-06-03	Robinson Harriet L.	Compositions and methods for generating an immune response
CN1312275A (zh) *	2000-03-07	2001-09-12	上海博德基因开发有限公司	一种新的多肽——人热休克蛋白15和编码这种多肽的多核苷酸
US7094408B2 (en)	2000-04-28	2006-08-22	The United States Of America As Represented By The Department Of Health And Human Services	Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
ATE318908T1 (de)	2000-05-18	2006-03-15	Geneart Gmbh	Synthetische gene für gagpol und deren verwendungen
AUPQ776100A0 (en)	2000-05-26	2000-06-15	Australian National University, The	Synthetic molecules and uses therefor
WO2002032943A2 (en)	2000-08-14	2002-04-25	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
PL212047B1 (pl)	2000-11-23	2012-08-31	Bavarian Nordic As	Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
CU23235A1 (es)	2001-02-28	2007-09-26	Ct Ingenieria Genetica Biotech	POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
IL160809A0 (en)	2001-09-20	2004-08-31	Glaxo Group Ltd	HIV-gag CODON-OPTIMISED DNA VACCINES
AUPR842501A0 (en)	2001-10-23	2001-11-15	Epipop Pty Ltd	A method for identification and development of therapeutic agents
ATE420658T1 (de)	2002-03-19	2009-01-15	Powderject Res Ltd	Imidazoquinolinamine als adjuvantien für hiv dna vakzine
RU2238946C2 (ru)	2002-04-22	2004-10-27	Государственный научный центр вирусологии и биотехнологии "Вектор"	Искусственный белок-иммуноген tci, содержащий множественные ctl-эпитопы основных антигенов вич-1, искусственный ген tci, кодирующий полиэпитопный белок-иммуноген tci
CN102703393A (zh)	2002-05-16	2012-10-03	巴法里安诺迪克有限公司	表达插入痘病毒基因组中的同源基因的重组痘病毒
CA2483640A1 (en)	2002-05-16	2003-11-27	Bavarian Nordic A/S	Fusion protein of hiv regulatory/accessory proteins
US7501127B2 (en)	2002-05-16	2009-03-10	Bavarian Nordic A/S	Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
AU2003245729A1 (en)	2002-06-27	2004-01-19	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating a cytotoxic t lymphocyte immune response
EP1638993A4 (en)	2003-06-10	2007-05-09	Univ Melbourne	IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
CA2539325C (en)	2003-09-17	2016-03-22	Duke University	Consensus/ancestral immunogens
WO2005028634A2 (en)	2003-09-18	2005-03-31	Emory University	Improved mva vaccines
WO2005030964A1 (en)	2003-09-24	2005-04-07	Oxxon Therapeutics Limited	Hiv pharmaccines
GB0323840D0 (en)	2003-10-10	2003-11-12	Ist Superiore Sanita	Vaccines
EP1687022A4 (en)	2003-11-12	2008-02-13	Medical Res Council	RENTA: HIV IMMUNOGEN, AND USES OF RENTA
US20090169503A1 (en) *	2004-07-09	2009-07-02	The Government Of The United States, As Represented By The Secretary Of Dept Of H&Hs	Dna-based vaccination of retroviral-infected individuals undergoing treatment
GB0417494D0 (en)	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine
US9453239B2 (en)	2004-08-27	2016-09-27	Emory University	Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
US20060095241A1 (en)	2004-10-29	2006-05-04	Microsoft Corporation	Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8000900B2 (en)	2004-09-21	2011-08-16	Microsoft Corporation	Association-based predictions of pathogen characteristics
US8478535B2 (en)	2004-10-29	2013-07-02	Microsoft Corporation	Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060160070A1 (en)	2004-10-29	2006-07-20	Microsoft Corporation	Association-based epitome design
WO2006123256A2 (en)	2005-02-24	2006-11-23	Medical Research Council	Hivcon: an hiv immunogen and uses thereof
KR20080043775A (ko) *	2005-07-11	2008-05-19	글로브이뮨	표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
BRPI0504117A (pt)	2005-09-05	2007-05-22	Fundacao De Amparo A Pesquisa	epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
SG170092A1 (en)	2006-03-10	2011-04-29	Peptcell Ltd	Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
GB0608368D0 (en)	2006-04-28	2006-06-07	Isis Innovation	Process for making Oligopeptides
CA2670804A1 (en)	2006-05-19	2007-11-29	Sanofi Pasteur Inc.	Immunological composition
DK2062023T4 (en)	2006-08-25	2017-02-20	The Government Of The Us Secretary Dept Of Health And Human Services	INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS
EP2143791B1 (en)	2007-03-28	2014-04-23	Hiroshima University	Chicken embryonic stem cell and method for evaluation thereof
US8198079B2 (en) *	2007-04-26	2012-06-12	Merck Sharp & Dohme Corp.	Synthetic expression vectors for insect cells
WO2009009743A2 (en) *	2007-07-12	2009-01-15	Institute For Advance Study	Sequence optimization for expression of a foreign gene
CN101951931A (zh)	2008-01-16	2011-01-19	欧宝治疗私人有限公司	免疫调节组合物和其用途
CA2730742C (en)	2008-07-16	2017-05-23	Baylor Research Institute	Hiv vaccine based on targeting maximized gag and nef to dendritic cells
US8198062B2 (en)	2008-08-29	2012-06-12	Dsm Ip Assets B.V.	Hydrolases, nucleic acids encoding them and methods for making and using them
US8709775B2 (en)	2008-08-29	2014-04-29	Dsm Ip Assets B.V.	Hydrolases, nucleic acids encoding them and methods for making and using them
EP2161279A1 (en)	2008-08-29	2010-03-10	Centre National de la Recherche Scientifique	Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
WO2010037402A1 (en) *	2008-10-02	2010-04-08	Dako Denmark A/S	Molecular vaccines for infectious disease
WO2010059732A1 (en)	2008-11-18	2010-05-27	Beth Israel Deaconess Medical Center	Antiviral vaccines with improved cellular immunogenicity
JP2013505256A (ja)	2009-09-17	2013-02-14	サノフィパストゥールインコーポレイテッド	Ｈｉｖ用の免疫学的組成物
CA2767924A1 (en) *	2009-10-08	2011-04-14	Bavarian Nordic A/S	Generation of a broad t-cell response in humans against hiv
WO2011047324A1 (en)	2009-10-16	2011-04-21	The U.S.A. As Represented By The Secretary , Department Of Health And Human Services .	Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
US20130195904A1 (en)	2010-01-04	2013-08-01	National University Of Singapore	Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
WO2012062873A2 (en)	2010-11-10	2012-05-18	Laboratorios Del Dr. Esteve, S.A.	Highly immunogenic hiv p24 sequences
EP2620446A1 (en)	2012-01-27	2013-07-31	Laboratorios Del Dr. Esteve, S.A.	Immunogens for HIV vaccination
EP3972642A1 (en)	2019-05-22	2022-03-30	Aelix Therapeutics S.L.	Dosage regimens for vaccines
CA3161633A1 (en)	2019-11-14	2021-05-20	Aelix Therapeutics, S.L.	Dosage regimens for vaccines

2012
- 2012-01-27 EP EP12382031.8A patent/EP2620446A1/en not_active Withdrawn
2013
- 2013-01-28 NZ NZ734689A patent/NZ734689A/en unknown
- 2013-01-28 IN IN6164DEN2014 patent/IN2014DN06164A/en unknown
- 2013-01-28 RU RU2018104969A patent/RU2721274C2/ru active
- 2013-01-28 RU RU2014135053A patent/RU2648791C2/ru active
- 2013-01-28 EP EP13701288.6A patent/EP2807185B1/en active Active
- 2013-01-28 EP EP22195110.6A patent/EP4163290A1/en active Pending
- 2013-01-28 NZ NZ723229A patent/NZ723229A/en unknown
- 2013-01-28 NZ NZ628756A patent/NZ628756A/en unknown
- 2013-01-28 JP JP2014553750A patent/JP6306514B2/ja active Active
- 2013-01-28 ES ES13701288T patent/ES2932407T3/es active Active
- 2013-01-28 US US14/374,334 patent/US9988425B2/en active Active
- 2013-01-28 MX MX2014009091A patent/MX358711B/es active IP Right Grant
- 2013-01-28 WO PCT/EP2013/051596 patent/WO2013110818A2/en not_active Ceased
- 2013-01-28 CN CN201380006995.6A patent/CN104080800B/zh active Active
- 2013-01-28 CN CN201910705866.5A patent/CN110372798A/zh active Pending
- 2013-01-28 KR KR1020197018840A patent/KR102140778B1/ko active Active
- 2013-01-28 BR BR112014018396-1A patent/BR112014018396B1/pt active IP Right Grant
- 2013-01-28 KR KR1020147023946A patent/KR102108149B1/ko active Active
- 2013-01-28 CA CA2862172A patent/CA2862172C/en active Active
- 2013-01-28 AU AU2013213564A patent/AU2013213564B2/en active Active
2014
- 2014-07-16 ZA ZA2014/05204A patent/ZA201405204B/en unknown
- 2014-07-23 IL IL233771A patent/IL233771B/en active IP Right Grant
- 2014-07-25 MX MX2018010483A patent/MX2018010483A/es unknown
2017
- 2017-09-28 US US15/718,635 patent/US10815278B2/en active Active
2018
- 2018-03-08 JP JP2018041572A patent/JP6749357B2/ja active Active
- 2018-05-03 US US15/970,216 patent/US11325946B2/en active Active
- 2018-05-10 AU AU2018203264A patent/AU2018203264B2/en active Active
2019
- 2019-08-11 IL IL268629A patent/IL268629B/en active IP Right Grant
2021
- 2021-04-29 US US17/244,042 patent/US11919926B2/en active Active

Publication	Publication Date	Title
JP2015509707A5 (2)	2016-03-17
US12162907B2 (en)	2024-12-10	Subunit vaccine for treatment or prevention of a respiratory tract infection
RU2014135053A (ru)	2016-03-27	Иммуногены для вакцинации против вич
CN104884082B (zh)	2017-09-22	用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
JP2008529558A5 (2)	2009-04-02
JP2016533332A5 (2)	2017-11-02
JP2014530010A5 (2)	2016-09-29
FI2970398T3 (fi)	2024-08-06	Rsv f -prefuusioproteiineja ja niiden käyttö
JP2018512856A5 (2)	2019-05-23
JP2012501959A5 (2)	2012-10-11
US9388225B2 (en)	2016-07-12	Modified coiled coil type proteins having improved properties
JP2013532971A5 (2)	2014-08-14
JP2008056679A5 (2)	2010-03-18
JP2013507907A5 (2)	2013-11-28
CN114213548B (zh)	2024-10-29	同时诱导抗多种病毒的免疫应答的方法
TW202130363A (zh)	2021-08-16	變異型ｒｓｖｆ蛋白質及其利用
TW200844230A (en)	2008-11-16	Signaling peptides
CN117279659A (zh)	2023-12-22	人偏肺病毒疫苗
JP2016508143A5 (2)	2017-01-12
JP2012516140A5 (2)	2013-03-14
JP2014504297A5 (2)	2014-04-17
ES2713962T3 (es)	2019-05-24	Vacuna para prevenir la enfermedad de edema porcino
JP2016520534A5 (2)	2017-04-13
CN107344969A (zh)	2017-11-14	一种纳米流感疫苗及构建方法和应用
JP2006523185A5 (2)	2007-05-10